Macrólidos y cetólidos

Shiomi, 2002, Discovery of new macrolides, 1 Kucers A, Crowe S, Grayson ML, Hoy JF, editors. The Use of Antibiotics. 5.a ed. Oxford: Butterworth Heinemann; 1997. Zhanel, 2001, Review of macrolides and ketolides, Drugs, 61, 443, 10.2165/00003495-200161040-00003 Balfour, 2001, Telithromycin, Drugs, 61, 815, 10.2165/00003495-200161060-00016 Namour, 2001, Pharmacokinetics of the new ketolide telithomycin (HMR 3647) administered in ascending single and multiples doses, Antimicrob Agents Chemother, 45, 170, 10.1128/AAC.45.1.170-175.2001 Carbon, 1998, Pharmacodynamics of macrolides, azalides and streptogramins: effect on extracellular pathogens, Clin Infect Dis, 27, 28, 10.1086/514619 Carbon, 1995, Clinical relevance on intracellular and extracellular concentrations of macrolides, Infection, 23, 10, 10.1007/BF02464953 Morris, 1996, High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose, Eur J Clin Microbiol Infect Dis, 10, 859, 10.1007/BF01975842 2009 Guay, 2001, Pharmacokinetics and tolerability of extended-release clarithromycin, Clin Ther, 23, 566, 10.1016/S0149-2918(01)80060-6 Girard, 2005, Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models, J Antimicrob Chemother, 56, 365, 10.1093/jac/dki241 Williams, 1993, Comparison of macrolides antibiotics, J Antimicrob Chemother, 31, 11, 10.1093/jac/31.suppl_C.11 Eisenberg, 1994, Azithromycin and clarithromycin, 52 Schlossberg, 1995, Azithromycin and clarithromycin, Med Clin North Am, 79, 803, 10.1016/S0025-7125(16)30040-2 Dever, 1993, Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi, Antimicrob Agents Chemother, 37, 1704, 10.1128/AAC.37.8.1704 Hamilton-Miller, 1992, In vitro activities of 14, 15 and 16 membered macrolides against gram-positive cocci, J Antimicrob Chemother, 29, 141, 10.1093/jac/29.2.141 Landinez, 1992, In vitro activity of azitromycin and tetracycline against 358 clinical isolates of Brucella mellitensis, Eur J Clin Microbiol Infect Dis, 11, 265, 10.1007/BF02098096 Amsden, 1999, Pneumoncoccal macrolide resistance-myth or reality?, J Antimicrob Chemother, 44, 1, 10.1093/jac/44.1.1 Felmingham, 2001, Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens, J Antimicrob Chemother, 48, 33, 10.1093/jac/48.suppl_2.33 Douthwaite, 2001, Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site, J Antimicrob Chemother, 48, 1, 10.1093/jac/48.suppl_2.1 Douthwaite, 2001, Structure-activity relationships of ketolides vs. macrolides, Clin Microbiol Infect, 7, 11, 10.1046/j.1469-0691.2001.0070s3011.x Goldman, 1990, Role of protonated and neutral forms of macrolides in binding to ribosomes from gram-positive and gram-negative bacteria, Antimicrob Agents Chemother, 34, 426, 10.1128/AAC.34.3.426 Odenholt, 2001, Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens, Antimicrob Agents Chemother, 45, 23, 10.1128/AAC.45.1.23-29.2001 Labro, 1993, Modulation of human polymorphonuclear neutrophil function by macrolides: preliminary data concerning dirithromycin, J Antimicrob Chemother, 31, 51, 10.1093/jac/31.suppl_C.51 Mizukane, 1994, Comparative in vitro exoenzyme-suppresing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa, Antimicrob Agents Chemother, 38, 528, 10.1128/AAC.38.3.528 Howe, 1997, Macrolides for the treatment of Pseudomonas aeruginosa infections?, J Antimicrob Chemother, 40, 153, 10.1093/jac/40.2.153 Leclercq, 2001, Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin, J Antimicrob Chemother, 48, 9, 10.1093/jac/48.suppl_2.9 Leclercq, 1991, Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification, Antimicrob Agents Chemother, 35, 1267, 10.1128/AAC.35.7.1267 Liu, 2002, Activity of the ketolide telithromycin is refractory to erm monomethylation of bacterial rRNA, Antimicrob Agents Chemother, 46, 1629, 10.1128/AAC.46.6.1629-1633.2002 Gay, 2000, The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: A 6-year population-based assesment, J Infect Dis, 182, 1417, 10.1086/315853 Díaz, 2009, Correlación entre la prescripción de antibióticos y el descenso de las resistencias a antimicrobianos en el área de salud de Zamora, Enferm Infecc Microbiol Clin, 27, 153, 10.1016/j.eimc.2008.03.003 Betriu, 2002, Prevalence of macrolide and tetracycline resistance mechanims in Streptococcus pyogenes isolates and in vitro susceptibility to telithromycin, J Antimicrob Chemother, 50, 436, 10.1093/jac/dkf128 1995 1997 Schonwald, 1991, Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia, Eur J Clin Microbiol Infect Dis, 10, 877, 10.1007/BF01975847 Gleason, 1999, Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia, Arch Intern Med, 159, 2562, 10.1001/archinte.159.21.2562 Stahl, 1999, Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia, Arch Intern Med, 159, 2576, 10.1001/archinte.159.21.2576 Martínez, 2003, Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia, Clin Infect Dis, 36, 389, 10.1086/367541 Garcia, 2005, Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a β-lactam agent versus a β-lactam agent alone, Eur J Clin Microbiol Infect Dis, 24, 190, 10.1007/s10096-005-1295-9 Baddour, 2004, Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia, Am J Respir Crit Care Med, 170, 440, 10.1164/rccm.200311-1578OC Waterer, 2005, Monotherapy versus combination antimicrobial therapy for pneumococcal pneumonia, Curr Opin Infect Dis, 18, 157, 10.1097/01.qco.0000160906.02308.3c Rodriguez, 2007, Combination antibiotic therapy improves survival in patients with community –acquired pneumonia and shock, Crit Care Med, 35, 1493, 10.1097/01.CCM.0000266755.75844.05 Dudas, 2000, Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals, Ann Pharmacother, 34, 446, 10.1345/aph.19174 Metersky, 2007, Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones, Chest, 131, 466, 10.1378/chest.06-1426 Houck, 2001, Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states:1993, 1995 and 1997, Chest, 119, 1420, 10.1378/chest.119.5.1420 Brown, 2003, Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database, Chest, 123, 1503, 10.1378/chest.123.5.1503 Lodise, 2007, Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia, Antimicrob Agents Chemother, 51, 3977, 10.1128/AAC.00006-07 Reyes Calzada, 2007, Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and readmission, Repir Med, 101, 1909, 10.1016/j.rmed.2007.04.018 Charles, 2008, The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy, Clin Infect Dis, 46, 1513, 10.1086/586749 Restrepo, 2009, Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia, Eur Respir J, 33, 153, 10.1183/09031936.00054108 Tessmer, 2009, Impact of intravenous β-lactam/macrolide versus β-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia, J Antimicrob Chemother, 63, 1025, 10.1093/jac/dkp088 Handsfield, 1994, Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea, Sexually Transmitted Dis, 21, 107, 10.1097/00007435-199403000-00010 Girgis, 1999, Azitromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance, Antimicrob Agents Chemother, 43, 1441, 10.1128/AAC.43.6.1441 Jackson, 1999, Safety effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease, J Antimicrob Chemother, 44, 411, 10.1093/jac/44.3.411 Stone, 2002, Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflamation and cardiac events in patients with acute coronary syndromes: South thames trial of antibiotics in myocardial infarction and unstable angina (STAMINA), Circulation, 106, 1219, 10.1161/01.CIR.0000027820.66786.CF Yassim, 2001, Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections, Exp Opin Invest Drugs, 10, 353, 10.1517/13543784.10.2.353 Catnach, 1992, Erythromycin and the gut, Gut, 33, 397, 10.1136/gut.33.3.397 Ray, 2004, Oral erythromycin and the risk of sudden death from cardiac causes, NEJM, 351, 1089, 10.1056/NEJMoa040582 Ross, 2007, The FDA and the case of Ketek. 1, N Engl J Med, 356, 1601, 10.1056/NEJMp078032 Clay, 2006, Brief communication: Severe hepatotoxicity of telithromycin: Three case reports and literature review, Ann Intern Med, 144, 415, 10.7326/0003-4819-144-6-200503210-00121